Jamp ASA Pregnancy

• Pregnancy of Jamp ASA in details
• Jamp ASA breastfeeding
• Jamp ASA reviews

Pregnancy of Jamp ASA in details

Jamp ASA has not been formally assigned to pregnancy category by the FDA. However, Jamp ASA is considered to be in pregnancy category D by the FDA if full dose Jamp ASA is taken in the third trimester. Use of nonsteroidal anti-inflammatory drugs during the third trimester of pregnancy should be avoided due to effects on the fetal cardiovascular system (closure of the ductus arteriosus). Jamp ASA use in pregnancy has been associated with alterations in both maternal and fetal hemostasis. In addition, high doses have been associated with increased perinatal mortality, intrauterine growth retardation, and teratogenic effects. During the first two trimesters of pregnancy, Jamp ASA should only be given during pregnancy when clearly needed and when benefit outweighs risk. In 1990, the FDA issued a warning that it is especially important not to use Jamp ASA during the last trimester of pregnancy unless specifically directed to do so by a physician because it may cause problems in the unborn child or complications during delivery.

Increased maternal bleeding can occur during delivery when Jamp ASA is used 1 week prior to and/or during labor and delivery. Prolonged gestation and labor have been reported due to Jamp ASA's inhibition of prostaglandin. A study of the use of low-dose Jamp ASA (60 mg per day) to prevent and treat preeclampsia in 9364 pregnant women (the Collaborative Low-dose Jamp ASA Study in Pregnancy--CLASP) did "not support routine prophylactic or therapeutic administration of antiplatelet therapy in pregnancy to all women at increased risk of preeclampsia or IUGR." In that study, no excess of intraventricular hemorrhage, neonatal bleeds, or mortality attributable to bleeding were observed. The investigators did identify a possible role for low-dose Jamp ASA in the treatment of early-onset preeclampsia severe enough to need very preterm delivery. Another study of low-dose Jamp ASA (follow-up from the Italian Study of Jamp ASA in Pregnancy) has suggested that "low dose Jamp ASA in pregnancy is safe with respect to the risks of malformation and of major impairment in development at 18 months of age." High-dose Jamp ASA (2 g per day) has been associated with stillbirths, cerebral hemorrhage, oculoauriculovertebral dysplasia, neonatal salicylate toxicity, constricted ductus arteriosus, cyclopia, and neonatal acidosis. Some cases of congenital heart defects have been reported. However, a case control study of Jamp ASA use in the first trimester concluded that Jamp ASA "does not increase the risk of congenital heart defects in relation to that of other structural malformations."

See references

Jamp ASA breastfeeding

Jamp ASA is excreted into human milk in small amounts. Peak milk salicylate levels have been reported at nine hours after maternal dosing (and measured at 1.1 mg/dL). Use of large doses of Jamp ASA can result in rashes, platelet abnormalities, and bleeding in nursing infants. Because of a single case report of metabolic acidosis, the American Academy of Pediatrics characterizes Jamp ASA as a drug that has been "associated with significant effects on some nursing infants and should be given to nursing mothers with caution."

See references

References for pregnancy information

1. Karlowicz MG, White LE "Severe intracranial hemorrhage in a term neonate associated with maternal Jamp ASA ingestion." Clin Pediatr (Phila) 32 (1993): 740-3
2. Subtil D, Deruelle P, Trillot N, Jude B "Preclinical phase of polycythemia vera in pregnancy." Obstet Gynecol 98(5 Pt 2) (2001): 945-7
3. Leonhardt A, Bernert S, Watzer B, Schmitz-Ziegler G, Seyberth HW "Low-dose Jamp ASA in pregnancy: maternal and neonatal Jamp ASA concentrations and neonatal prostanoid formation." Pediatrics 111 (2003): e77-81
4. Kozer E, Nikfar S, Costei A, Boskovic R, Nulman I, Koren G "Jamp ASA consumption during the first trimester of pregnancy and congenital anomalies: A meta-analysis." Am J Obstet Gynecol 187 (2002): 1623-30
5. Li DK, Liu L, Odouli R "Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study." BMJ 327 (2003): 368
6. Parazzini F, Bortolus R, Chatenoud L, Restelli S, Benedetto C "Follow-up of children in the italian study of Jamp ASA in pregnancy." Lancet 343 (1994): 1235
7. "Product Information. Bayer Jamp ASA (Jamp ASA)." Bayer, West Haven, CT.
8. Schoenfeld A, Bar Y, Merlob P, Ovadia Y "NSAIDs: maternal and fetal considerations." Am J Reprod Immunol 28 (1992): 141-7
9. "Clasp: a randomised trial lf low-dose Jamp ASA for the prevention and treatment of pre-eclampsia among 9364 pregnant women." Lancet 343 (1994): 619-29

References for breastfeeding information

1. Committee on Drugs, 1992 to 1993 "The transfer of drugs and other chemicals into human milk." Pediatrics 93 (1994): 137-50
2. "Product Information. Bayer Jamp ASA (Jamp ASA)." Bayer, West Haven, CT.
3. Erickson SH, Oppenheim GL "Jamp ASA in breast milk." J Fam Pract 8 (1979): 189-90

Reviews

Consumer reviews

There are no reviews yet. Be the first to write one!

Your name:  Email:  Spam protection:  < Type 14 here

Information checked by Dr. Sachin Kumar, MD Pharmacology